Low-Dose Oral Minoxidil during Chemotherapy: A Review of the Mechanism and Current Evidence

Thumbnail Image

Files

Low-Dose Oral Minoxidil during Chemotherapy_2025.pdf (737.89 KB)
Identifiers
URI: https://hdl.handle.net/11268/16572
DOI: 10.1159/000548112

Publication date

2025

Authors

Kearney, Caitlin A.
Gordon, Allison
Markova, Alina
Freites Martínez, Azael David
Tattersall, Ian W.

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

SDG

goal-3

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Chemotherapy-induced alopecia (CIA) significantly impacts patients’ quality of life. While low-dose oral minoxidil (LDOM) shows promise in treating CIA after chemotherapy completion, its safety and efficacy when given during active chemotherapy remain unclear. This review examined existing literature on CIA pathogenesis, minoxidil’s mechanism of action, and LDOM efficacy to explore its potential use during chemotherapy.

Description

UNESCO Subjects

Enfermedad de la piel
Cáncer
Tratamiento médico

Keywords

Bibliographic reference

Kearney, C. A., Gordon, A., Markova, A., Freites-Martinez, A., Tattersall, I. W., Shapiro, J., Lacouture, M. E., & Lo Sicco, K. I. (2025). Low-dose oral minoxidil during chemotherapy: A review of the mechanism and current evidence. Skin Appendage Disorders, 1-9. https://doi.org/10.1159/000548112
Editor's version
https://doi.org/10.1159/000548112

Type of document

journal article

Collections

Área de Ciencias de la Salud
Attribution-NonCommercial 4.0 International

La licencia de este ítem se describe como Attribution-NonCommercial 4.0 International